HER2阳性乳腺癌的基因组特征与新辅助曲妥珠单抗联合化疗疗效——ACOSOG Z1041(Alliance)试验结果
研究对48例HER2阳性乳腺癌患者的治疗前肿瘤活检和血液进行全基因组和外显子组测序,并对42例活检组织进行RNA测序,其中24例(50%)达到病理完全缓解(pCR)。RNA-seq分型的HER2富集亚型较luminal、基底样或正常样亚型更易达到pCR(19/27 vs 3/15;P=0.0032),ERBB2扩增缺失或低水平的病例达到pCR的可能性较低(7/8 vs 17/40;P=0.048)。
要点
- HER2富集亚型较其他亚型更易达到pCR(19/27 vs 3/15;P=0.0032)。
- ERBB2无扩增或低水平扩增病例达到pCR的可能性较低(7/8 vs 17/40;P=0.048)。
- 突变事件产生的neoantigen总体与pCR无关,达到pCR的肿瘤一致表达免疫特征。
核心结论
- 这些特征的识别提示,或许有可能在诊断时预测哪些HER2阳性乳腺癌患者不会对化疗联合曲妥珠单抗治疗产生应答。
研究设计与样本
- ACOSOG Z1041试验(NCT00513292)设计用于比较不同新辅助化疗联合曲妥珠单抗方案的pCR率,最终未发现差异。
- 除37例Z1041病例的组织外,另从一项单机构研究(NCT00353483)获取11例类似治疗的病例,共48例。
- 从48例的治疗前肿瘤活检和血液中提取基因组DNA,进行全基因组和外显子组测序,并从42例肿瘤活检组织生成RNA-seq图谱。
主要发现
- 本队列中24例(50%)达到pCR。
- RNA-seq分析归为HER2富集亚型的病例较luminal、基底样或正常样亚型更易达到pCR(19/27 vs 3/15;P=0.0032)。
- 突变事件产生推定的活性neoantigen,但总体与pCR无关。
- ERBB2和GRB7是融合事件中最常见的基因,ERBB2位点基因组拷贝数分析显示无可观察或低水平ERBB2扩增的病例达到pCR的可能性较低(7/8 vs 17/40;P=0.048)。
- 在达到pCR的病例中,肿瘤一致表达可能有助于治疗应答的免疫特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15-30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College of Surgeons Oncology Group Z1041 trial (NCT00513292) was designed to compare the pathologic complete response (pCR) rate of distinct regimens of neoadjuvant chemotherapy and trastuzumab, but ultimately identified no difference. PATIENTS AND METHODS: In supplement to tissues from 37 Z1041 cases, 11 similarly treated cases were obtained from a single institution study (NCT00353483). We have extracted genomic DNA from both pre-treatment tumor biopsies and blood of these 48 cases, and performed whole genome (WGS) and exome sequencing. Coincident with these efforts, we have generated RNA-seq profiles from 42 of the tumor biopsies. Among patients in this cohort, 24 (50%) achieved a pCR. RESULTS: We have characterized the genomic landscape of HER2-positive breast cancer and investigated associations between genomic features and pCR. Cases assigned to the HER2-enriched subtype by RNA-seq analysis were more likely to achieve a pCR compared to the luminal, basal-like, or normal-like subtypes (19/27 versus 3/15; P = 0.0032). Mutational events led to the generation of putatively active neoantigens, but were overall not associated with pCR. ERBB2 and GRB7 were the genes most commonly observed in fusion events, and genomic copy number analysis of the ERBB2 locus indicated that cases with either no observable or low-level ERBB2 amplification were less likely to achieve a pCR (7/8 versus 17/40; P = 0.048). Moreover, among cases that achieved a pCR, tumors consistently expressed immune signatures that may contribute to therapeutic response. CONCLUSION: The identification of these features suggests that it may be possible to predict, at the time of diagnosis, those HER2-positive breast cancer patients who will not respond to treatment with chemotherapy and trastuzumab. CLINICALTRIALS.GOV IDENTIFIERS: NCT00513292, NCT00353483.
引用
- Lesurf R, Griffith OL, Griffith M, et al. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017. PMID: 28453704. doi:10.1093/annonc/mdx048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。